Recent systematic reviews have shown that SGLT2 inhibitors reduce liver fat content by approximately 20% and improve liver enzymes in MASLD patients [21,22]. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.